Summary
The Europe Urinalysis Test Market would witness market growth of 5.7% CAGR during the forecast period (2023-2029).
The urinalysis test is growing as a result of massive investments in the creation of urine testing kits for use at home in the diagnosis of diseases. In addition, the development of at-home urine tests is being pursued by organizations to offer advice on nutrition and lifestyle choices. For routine urine examinations, emerging nations with high price sensitivity favored affordable yet similarly functional analyzers. Thus, the creation of inexpensive urinalysis tests is anticipated to drive market expansion.
The test includes a number of microscopic, visual, and chemical tests that reveal cells, protein levels, creatinine levels, and elements like crystals in the urine that aid in the identification of various disorders. Finding the source of symptoms, including back pain, stomach pain, and painful urination, also helps. Additionally, it is projected that the expansion of the urinalysis market would be aided by factors such as an aging population, an increase in government activities to raise public awareness, and technological advancements in urinalysis.
Diabetes affects about 8.5 million people in Germany. This resulted from a review of the data from the Robert Koch Institute’s survey and investigation across the country. Estimates say about 2 million people have diabetes but don’t know it. Over the next twenty years, the number of people with type 2 diabetes in Germany will keep increasing. It is estimated that as many as 12 million people could have metabolic disorders by 2040. Thus, with the rising cases of diabetes, the demand for its diagnosis will also increase, providing more growth opportunities for the urinalysis test market growth.
The Germany market dominated the Europe Urinalysis Test Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $299.6 Million by 2029. The UK market is anticipated to grow at a CAGR of 4.7% during (2023 - 2029). Additionally, The France market would experience a CAGR of 6.6% during (2023 - 2029).
Based on Product, the market is segmented into Consumables and Instruments. Based on Application, the market is segmented into Disease Screening and Pregnancy & Fertility. Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics and Homecare. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Cardinal Health, Inc., Siemens Healthineers AG (Siemens AG), ACON Laboratories, Inc., Sysmex Corporation, Bio-Rad Laboratories, Inc., Arkray, Inc., Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd., and Becton, Dickinson and Company.
Scope of the Study
Market Segments covered in the Report:
By Product
• Consumables
• Instruments
By Application
• Disease Screening
• Pregnancy & Fertility
By End User
• Diagnostic Laboratories
• Hospitals & Clinics
• Homecare
By Country
• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe
Companies Profiled
• Cardinal Health, Inc.
• Siemens Healthineers AG (Siemens AG)
• ACON Laboratories, Inc.
• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• Arkray, Inc.
• Abbott Laboratories
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Becton, Dickinson and Company
Unique Offerings
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free
